Article Sidebar

PDF (Tiếng Việt)
Published: 2023-11-30
Abstract Views: 308
Views PDF (Tiếng Việt): 348
DOI: https://doi.org/10.52852/tcncyh.v172i11.2055
Issue
Vol. 172 No. 11 (2023)
Section
Các bài báo
How to Cite
Doanh, L. H., Lan, P. T., Phương, P. T. M., Vinh, N. T. H., My, L. H., Thùy N. T. T., Ghi Đào H., & Huyền, T. T. (2023). 1. Serum levels of Interleukin-1 beta, Interleukin-6 and Interleukin-8 in generalized erythema multiforme. Journal of Medical Research, 172(11), 1-10. https://doi.org/10.52852/tcncyh.v172i11.2055

1. Serum levels of Interleukin-1 beta, Interleukin-6 and Interleukin-8 in generalized erythema multiforme

Le Huu Doanh, Pham Thi Lan, Pham Thi Minh Phuong, Nguyen Thi Ha Vinh, Le Huyen My, Nguyen Thi Thanh Thuy, Dao Huu Ghi, Tran Thi Huyen

Main Article Content

Abstract

Erythema multiforme (EM) is a mucocutaneous inflammatory condition characterized by distinctive clinical lesions. EM’s etiology and pathogenesis may be related to infections and the activity of immune cells and cytokines. This cross-sectional descriptive study aimed to assess the serum levels of interleukin (IL)-1 beta (β), IL-6, and IL-8 in generalized EM. A fluorescence covalent microbead immunosorbent assay was used to simultaneously detect multiple cytokines. The results showed that, in the EM group, serum concentrations of IL-1β, IL-6, and IL-8 were 6.9 ± 18.8 pg/ml; 147.4 ± 597.9 pg/ml and 231.6 ± 562.4, respectively. These concentrations were significantly lower than those in the healthy group (515.5 ± 640.8 pg/ml, 3321.5 ± 4186.7 pg/ml and 1396.8 ± 895.1 pg/ml, for IL-1β, IL-6, and IL-8, respectively (p < 0.001). Additionally, among EM patients with mucosal lesions, IL-6 serum levels were significantly higher than those in EM patients without mucosal lesions (756.8±1482.0 pg/ml vs. 38.6 ± 131.8 pg/ml, p < 0.01).

Article Details

Keywords

Generalized erythema multiform, herpes simplex virus, interleukin-1 beta, interleukin-6, interleukin-8

References

1. Roujeau JC, Mockenhaupt M. Erythema multiforme. Fitzpatrick’s Dermatology. 2019, Vol. I. McGraw Hill Education. pp. 723-733.
2. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993; 129(1): 92-96.
3. Puerta-Pena M, Velasco-Tamariz V. Herpes-Associated Erythema Multiforme. N Engl J Med. 2021; 384(19): 1848. doi:10.1056/NEJMicm2033090.
4. Amode R, Ingen-Housz-Oro S, Ortonne N, et al. Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. J Am Acad Dermatol. 2018; 79(1): 110-117. doi:10.1016/j.jaad.2018.03.013.
5. Trayes KP, Love G, Studdiford JS. Erythema Multiforme: Recognition and Management. Am Fam Physician. 2019; 100(2): 82-88.
6. Goyache Moreno A, Anniccherico Sanchez FJ. Antiepileptic-induced erythema multiforme with pulmonary involvement. Med Clin (Barc). 2022; 158(9): 444-445. doi:10.1016/j.medcli.2021.07.016.
7. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am. 2013; 57(4): 583-596. doi:10.1016/j.cden.2013.07.001.
8. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J. 2003; 9(1):1.
9. Akkurt ZM, Uçmak D, Türkcü G, Yüksel H, Yildiz K, Arıca M. Expression of interleukin-17 in lesions of erythema multiforme may indicate a role for T helper 17 cells. Cent-Eur J Immunol. 2014; 39(3): 370-376. doi:10.5114/ceji.2014.45950.
10. Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol. 2006; 155(4): 722-728. doi:10.1111/j.1365-2133.2006.07398.x.
11. Ho AW, Kupper TS. Soluble mediators of the cutaneous immune system. Fitzpatrick’s dermatology. 2019, Vol. I. McGraw Hill Education. pp. 159-192.
12. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm. 2013; 2013:165974. doi:10.1155/2013/165974.
13. Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013; 69(3): 496-498. doi:10.1016/j.jaad.2013.04.007.
14. Su SC, Mockenhaupt M, Wolkenstein P, et al. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017; 137(5): 1065-1073. doi:10.1016/j.jid.2016.11.034.